中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2015年
8期
20-22
,共3页
强直性脊柱炎%美洛昔康片%七味通痹口服液%肝肾亏虚证
彊直性脊柱炎%美洛昔康片%七味通痺口服液%肝腎虧虛證
강직성척주염%미락석강편%칠미통비구복액%간신우허증
ankylosing spondylitis%meloxicam%Qiweitongbi Oral Liquid%liver and kidney deficiency syndrome
目的：观察美洛昔康片联合七味通痹口服液治疗强直性脊柱炎( AS )肝肾亏虚证的临床疗效。方法将80例AS患者随机分为治疗组和对照组，各40例。治疗组患者口服美洛昔康片和七味通痹口服液，对照组患者口服柳氮磺胺嘧啶和双氯芬酸钠肠溶片。观察治疗后两组患者的关节疼痛、肿胀及整体功能分级、Keitel试验、双侧4字试验、Schober试验、肌腱附着点炎症情况；实验室指标包括血沉( ESR )，C反应蛋白( CRP )、X射线常规骶髂关节正位片或CT扫描及HLA－B27。结果治疗组的总有效率为85.00%，明显高于对照组的60.00%（ P＜0.05）；治疗组髋疼痛、膝疼痛、膝肿胀、踝疼痛、踝肿胀评分均较对照组改善显著（ P＜0.05或 P＜0.01）；治疗组前屈、侧屈、晨僵和Keitel试验评分均较对照组变化显著（ P＜0.05或 P＜0.01）；治疗组体征及关节外症状各项指标与对照组比较，差异均有统计学意义（ P＜0.05或 P＜0.01）；ESR，CRP，HLA－B27阳性及X线改变比较，治疗组各项指标变化均较对照组显著（ P＜0.05或P＜0.01）；治疗组不良反应明显少于对照组（ P＜0.05）。结论美洛昔康片结合七味通痹口服液治疗AS肝肾亏虚证疗效肯定且不良反应小。
目的：觀察美洛昔康片聯閤七味通痺口服液治療彊直性脊柱炎( AS )肝腎虧虛證的臨床療效。方法將80例AS患者隨機分為治療組和對照組，各40例。治療組患者口服美洛昔康片和七味通痺口服液，對照組患者口服柳氮磺胺嘧啶和雙氯芬痠鈉腸溶片。觀察治療後兩組患者的關節疼痛、腫脹及整體功能分級、Keitel試驗、雙側4字試驗、Schober試驗、肌腱附著點炎癥情況；實驗室指標包括血沉( ESR )，C反應蛋白( CRP )、X射線常規骶髂關節正位片或CT掃描及HLA－B27。結果治療組的總有效率為85.00%，明顯高于對照組的60.00%（ P＜0.05）；治療組髖疼痛、膝疼痛、膝腫脹、踝疼痛、踝腫脹評分均較對照組改善顯著（ P＜0.05或 P＜0.01）；治療組前屈、側屈、晨僵和Keitel試驗評分均較對照組變化顯著（ P＜0.05或 P＜0.01）；治療組體徵及關節外癥狀各項指標與對照組比較，差異均有統計學意義（ P＜0.05或 P＜0.01）；ESR，CRP，HLA－B27暘性及X線改變比較，治療組各項指標變化均較對照組顯著（ P＜0.05或P＜0.01）；治療組不良反應明顯少于對照組（ P＜0.05）。結論美洛昔康片結閤七味通痺口服液治療AS肝腎虧虛證療效肯定且不良反應小。
목적：관찰미락석강편연합칠미통비구복액치료강직성척주염( AS )간신우허증적림상료효。방법장80례AS환자수궤분위치료조화대조조，각40례。치료조환자구복미락석강편화칠미통비구복액，대조조환자구복류담광알밀정화쌍록분산납장용편。관찰치료후량조환자적관절동통、종창급정체공능분급、Keitel시험、쌍측4자시험、Schober시험、기건부착점염증정황；실험실지표포괄혈침( ESR )，C반응단백( CRP )、X사선상규저가관절정위편혹CT소묘급HLA－B27。결과치료조적총유효솔위85.00%，명현고우대조조적60.00%（ P＜0.05）；치료조관동통、슬동통、슬종창、과동통、과종창평분균교대조조개선현저（ P＜0.05혹 P＜0.01）；치료조전굴、측굴、신강화Keitel시험평분균교대조조변화현저（ P＜0.05혹 P＜0.01）；치료조체정급관절외증상각항지표여대조조비교，차이균유통계학의의（ P＜0.05혹 P＜0.01）；ESR，CRP，HLA－B27양성급X선개변비교，치료조각항지표변화균교대조조현저（ P＜0.05혹P＜0.01）；치료조불량반응명현소우대조조（ P＜0.05）。결론미락석강편결합칠미통비구복액치료AS간신우허증료효긍정차불량반응소。
Objective To observe the effect of meloxicam combined with Qiweitongbi Oral Liquid in treating ankylosing spondylitis(AS) with liver and kidney deficiency syndrome,and to investigate its symptoms,ESR,CRP,influence of frontal film and CT scanning of sacroiliac joint as well as the adverse reactions. Methods Totally 80 patients with AS were randomly divided into the treatment group and the control group,40 cases in each group. The treatment group was treated with oral Meloxicam Tablet and Qiweitongbi Oral Liq-uid,while the control group was treated with oral salazosulfadimidine and Diclofenac Sodium Enteric-Coated Tablets. The joint pain, joint swelling and overall function classifications,Keitel test,bilateral 4-word test,Schober test,inflammation of tendon attachment point after treatment were observed in the two groups;the laboratory indicators included ESR,CRP,X-ray routine frontal film or CT scanning of sacroiliac joint and HLA-B27. Results The total effective rate in the treatment group was 85. 00%,which was significantly higher than 60. 00% in control group( P < 0. 05);the hip pain,knee pain,knee swelling,ankle pain and ankle swelling score in the treatment group were significantly improved compared with the control group( P < 0. 05 or P < 0. 01);the anteflexion,lateroflexion,morning stiff-ness and the Keitel test score in the treatment group had significant changes compared with the control group( P < 0. 05 or P <0. 01). The body signs and extra-articular symptoms had statistical differences between the treatment group and the control group( P <0. 05 or P < 0. 01);the changes of ESR,CRP,HLA-B27 positive and X-ray in the treatment group were more significant compared with the control group( P < 0. 05 or P < 0. 01);the adverse reactions in the tneatment group were less than those in the control group ( P < 0. 05). Conclusion Meloxicam combined with Qiweitongbi Oral Liquid has definite effect and small adverse reactions in treating AS.
